Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AtriCure Yönetim

Yönetim kriter kontrolleri 2/4

AtriCure's CEO'su Mike Carrel, Nov2012 tarihinde atandı, in görev süresi 11.92 yıldır. in toplam yıllık tazminatı $ 8.75M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.2% maaş ve 90.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.36% ine doğrudan sahiptir ve bu hisseler $ 18.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.7 yıl ve 7.6 yıldır.

Anahtar bilgiler

Mike Carrel

İcra Kurulu Başkanı

US$8.7m

Toplam tazminat

CEO maaş yüzdesi	9.2%
CEO görev süresi	11.9yrs
CEO sahipliği	1.4%
Yönetim ortalama görev süresi	7.7yrs
Yönetim Kurulu ortalama görev süresi	7.6yrs

Son yönetim güncellemeleri

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Oct 02

Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

Sep 06

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

Jul 18

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

CEO Tazminat Analizi

Mike Carrel'un ücretlendirmesi AtriCure'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$9m	US$804k	-US$30m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$38m
Dec 31 2022	US$8m	US$795k	-US$46m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	US$53m
Mar 31 2022	n/a	n/a	US$52m
Dec 31 2021	US$8m	US$766k	US$50m
Sep 30 2021	n/a	n/a	US$45m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$6m	US$718k	-US$48m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$50m
Mar 31 2020	n/a	n/a	-US$46m
Dec 31 2019	US$6m	US$740k	-US$35m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$20m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$4m	US$714k	-US$21m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$20m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$4m	US$671k	-US$27m

Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 8.75M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).

Tazminat ve Kazançlar: Mike şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mike Carrel (53 yo)

11.9yrs

Görev süresi

US$8,749,289

Tazminat

Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President at AtriCure, Inc. since November 2012. Mr. Carrel has been Director at Axonics Inc. since February 27, 2019 an...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Carrel	CEO, President & Director	11.9yrs	US$8.75m	1.36% $ 18.3m
Angela Wirick	Chief Financial Officer	4.2yrs	US$2.92m	0.29% $ 3.8m
Douglas Seith	Chief Operating Officer	9.8yrs	US$3.50m	0.32% $ 4.3m
Salvatore Privitera	Chief Technical Officer	7.8yrs	US$2.13m	0.21% $ 2.9m
Karl Dahlquist	Chief Legal Officer	5.6yrs	US$2.13m	0.11% $ 1.4m
Vinayak Doraiswamy	Chief Scientific Officer	7.6yrs	US$1.78m	0.12% $ 1.7m
Valerie Storch-Willhaus	Vice President of Corporate Marketing & Communications	no data	Veri yok	Veri yok
Justin Noznesky	Chief Marketing & Strategy Officer	8.6yrs	US$1.78m	0.15% $ 2.0m
Deborah Yount	Chief Human Resources Officer	2.3yrs	US$1.92m	0.098% $ 1.3m

7.7yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: ATRC 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Carrel	CEO, President & Director	11.9yrs	US$8.75m	1.36% $ 18.3m
Sven Wehrwein	Independent Director	7.9yrs	US$227.47k	0.059% $ 800.6k
B. Johnson	Independent Director	7.6yrs	US$264.97k	0.091% $ 1.2m
Shlomi Nachman	Independent Director	less than a year	Veri yok	0.027% $ 362.2k
Robert White	Independent Chairman of the Board	11.6yrs	US$225.47k	0.20% $ 2.7m
Karen Prange	Independent Director	4.8yrs	US$219.97k	0.049% $ 661.2k
Maggie Yuen	Independent Director	3.3yrs	US$209.97k	0.018% $ 247.8k
Regina Groves	Independent Director	7.6yrs	US$232.47k	0.063% $ 850.1k
Deborah Telman	Independent Director	3.3yrs	US$212.47k	0.034% $ 463.7k

7.6yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ATRC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).

AtriCure Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

AtriCure, Inc., Annual General Meeting, May 13, 2024

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

AtriCure, Inc. Receives Expanded Ce-Mark Indication for Atriclip®? Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure, Inc. Provides Earnings Guidance for the Full Year 2024

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

AtriCure, Inc. Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure, Inc. Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc. to Report Q2, 2024 Results on Jul 30, 2024

AtriCure, Inc.(NasdaqGM:ATRC) dropped from Russell 2000 Value-Defensive Index

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock